Predictive Oncology Q1 2023 net loss $3.4M on revenue $0.2M; partnerships announced

Axe Compute Inc.

Net loss of $3.4M, diluted EPS loss $0.86; revenue $239.9K vs $314.6K in Q1 2022.
Cash $18.6M vs $22.1M at Dec 31, 2022; stockholders' equity $18.6M.
Gross margin fell to 50% from 65% due to sales mix.
Partnerships: Cancer Research Horizons, Integra Therapeutics, Cvergenx announced.
Appointed Veena Rao to Board and Pamela Bush as Chief Business Officer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Axe Compute Inc. reported financial results for three months ended March 31, 2023.

Period: three months ended March 31, 2023
Result: reported results

Exact text from the filing

On May 15, 2023, Predictive Oncology Inc. issued a press release attached hereto as Exhibit 99.1 announcing its financial results for the three months ended March 31, 2023.

View on SEC.gov

16 earnings releases filed in the last 30 days. Browse all earnings releases →

Axe Compute Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-003318

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.